Merck & Company Inc. (new) (MRK) was the best stock on the 30-component Dow Jones Industrial Average Index on June 16, rising 2.51% to close the day at $57.5 after closing the day prior at $56.09. Throughout the day, shares of MRK traded as high as $57.67 and as low as $56.13. Today’s advance came with about 22.04 million shares changing hands, compared to an average 30-day volume of 7.83 million for Merck & Company Inc. (new). The closing price today is below the 30-day volume weighted average price of $57.0 for MRK.
The share appreciation gives the Healthcare company a market capitalization of $155.26 billion based upon 2.77 billion shares outstanding. It also means that MRK has a price-to-book ratio of 3.54:1 and a price-to-earnings ratio of 34.6:1.
In the past 52 weeks, shares of MRK have traded as low as $45.69 and as high as $60.07. Technical traders will take note that at $57.5, shares of MRK are trading above their 200-day MA at $52.1. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move through or holding above them is typically regarded as bullish.
Who is MRK?
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health. The company’s 68000 are led by CEO Kenneth C. Frazier from the corporate headquarters at 2000 Galloping Hill Road.
For more information on MRK and other companies trading on the major exchanges, as well as the over the counter markets, or to be considered for contributing content for our distribution network, visit FinancialPress.com today.
All data provided by QuoteMedia and was accurate as of 4:00 PM ET.
FinancialPress.com is a leading publisher of market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. A complete disclaimer can be viewed here.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of FinancialPress.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://financialpress.com/legal-disclaimer/.